Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan;41(1):132-155.
doi: 10.1002/hpm.70034. Epub 2025 Nov 4.

Intermediaries and Development of Biopharmaceuticals: Evidence From the Innovation Policy in a Developing Country

Atiyeh Safardoust  1 , Fereidoun Mahboudi  2 , Soode Mirmohammadi  3 , Mohsen Pourqasem  3
Affiliations

Intermediaries and Development of Biopharmaceuticals: Evidence From the Innovation Policy in a Developing Country

Atiyeh Safardoust et al. Int J Health Plann Manage. 2026 Jan.

Abstract

Motivation: The biopharmaceutical industry in Iran has made significant progress in recent years, supported by multiple innovation policies aimed at its development. Nevertheless, challenges such as limited resources, skill and managerial gaps, weak networking, and restricted access to funding and incentives have hindered sustainable innovation.

Purpose: This study aims to examine the role of intermediaries in supporting biopharmaceutical companies and to analyze how innovation policies influence technological capabilities, networking, human capital development, and access to funding and incentives in Iran.

Approach and methods: A qualitative approach was employed, using purposive sampling to select 19 participants from the governmental, academic, and industrial sectors. Data were collected through semi-structured interviews and analyzed using Braun and Clarke's six-step thematic analysis (2006). Data credibility and validity were ensured through member checking, triangulation, and independent coding by two researchers.

Findings: The findings indicate that innovation policies have advanced across four main dimensions-exploitation of results and production, networking and facilitation, human capital, and funding and incentives-but each dimension faces specific challenges. Intermediaries, including accelerators, technology centers, industry associations, and specialized investment funds, play a key role in addressing these challenges by providing practical training, financial and technical support, facilitating cross-sector collaborations, and establishing professional networks, thereby fostering sustainable development and innovation in the biopharmaceutical sector.

Policy implications: Strengthening intermediaries and implementing targeted policies based on companies' real needs can enhance the effectiveness of innovation policies, reduce import dependence, and improve the global competitiveness of Iran's biopharmaceutical industry.

Keywords: biopharmaceuticals; developing countries; innovation policy; intermediaries.

PubMed Disclaimer

References

    1. B. N. Hogenhuis, E. A. Van Den Hende, and E. J. Hultink, “Unlocking the Innovation Potential in Large Firms Through Timely and Meaningful Interactions With Young Ventures,” International Journal of Innovation Management 21, no. 1 (2017): 1750009, https://doi.org/10.1142/s1363919617500098.
    1. J. L. Christensen, A. Schibany, and A. Vinding, “Collaboration Between Manufacturing Firms and Knowledge Institutions on Product Development: Evidence From Harmonised Surveys in Australia, Austria, Denmark, Norway and Spain,” in Innovative Networks: Co‐Operation in National Innovation Systems, (2001), 253–278.
    1. Bettanti, A., Lanati, A., & Missoni, A. (2021). Biopharmaceutical Innovation Ecosystems: A Theoretical Model and the Case of Lombardy.
    1. A. C. Szkodny and K. H. Lee, “Biopharmaceutical Manufacturing: Historical Perspectives and Future Directions,” Annual Review of Chemical and Biomolecular Engineering 13, no. 1 (2022): 141–165, https://doi.org/10.1146/annurev‐chembioeng‐092220‐125832.
    1. S. E. Khilji, T. Mroczkowski, and B. Bernstein, “From Invention to Innovation: Toward Developing an Integrated Innovation Model for Biotech Firms,” Journal of Product Innovation Management 23, no. 6 (2006): 528–540, https://doi.org/10.1111/j.1540‐5885.2006.00222.x.

Substances

LinkOut - more resources